Lexicon Pharmaceuticals (LXRX) Other Non Operating Income (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Other Non Operating Income data on file, last reported at $1.5 million in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $1.5 million, down 30.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 50.66% YoY), and the FY2025 annual result was $6.9 million, down 43.8% from the prior year.
• Other Non Operating Income grew to $1.5 million in Q1 2026 per LXRX's latest filing, from $1.3 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $4.1 million in Q2 2024 and troughed at $14000.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $1.6 million in 2025 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income sank 70.83% in 2022, then jumped 7250.0% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at $887000.0 in 2022, then surged by 170.8% to $2.4 million in 2023, then climbed by 17.78% to $2.8 million in 2024, then sank by 54.72% to $1.3 million in 2025, then advanced by 20.45% to $1.5 million in 2026.
• Business Quant data shows LXRX's Other Non Operating Income at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.6 million in Q3 2025.